Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

NCT02371603 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02371603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02371603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
February 11, 2015
Completion date
August 12, 2015
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia